Xinping Zhou

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Fluorescent Probe

Top Venues

Hematological oncology

Science advances

Cancer medicine

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Shuanghong Zhu, Yingwan Luo, Kongfei Li, Chen Mei, Yuxia Wang, Lingxu Jiang, Wei Wang, Qi Zhang, Wenli Yang, Wei Lang, Xinping Zhou, Lu Wang, Yanling Ren, Liya Ma, Li Ye, Xin Huang, Jianjun Chen, Jie Sun, Hong-Yan Tong
RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells. Science advances 10 (16) (2024)
Shuanghong Zhu, Yingwan Luo, Kongfei Li, Chen Mei, Yuxia Wang, Lingxu Jiang, Wei Wang, Qi Zhang, Wenli Yang, Wei Lang, Xinping Zhou, Lu Wang, Yanling Ren, Liya Ma, Li Ye, Xin Huang, Jianjun Chen, Jie Sun, Hong-Yan Tong
RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells. Science advances 10 (16) (2024)
Xinping Zhou, Wei Lang, Chen Mei, Yanling Ren, Liya Ma, Lingxu Jiang, Li Ye, Gaixiang Xu, Yingwan Luo, Lixia Liu, Shanbo Cao, Jia-Yue Qin, Hongyan Tong
Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia. Clinical and translational medicine 13 (7) (2023)
Wei Wang, Yudi Zhang, Wenli Yang, Yueyuan Han, Lingxu Jiang, Xiaozhen Liu, Wei Lang, Yingwan Luo, Shuanghong Zhu, Xinping Zhou, Lu Wang, Li Ye, Liya Ma, Hong-Yan Tong
Mutation landscape of normal karyotype myelodysplastic syndromes and their prognostic impact. American journal of hematology (2023)
Yanling Ren, Wei Lang, Chen Mei, Yingwan Luo, Li Ye, Lu Wang, Xinping Zhou, Gaixiang Xu, Liya Ma, Jie Jin, Hongyan Tong
Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome. Hematological oncology (2022)
Chen Mei, Li Ye, Yanling Ren, Xinping Zhou, Liya Ma, Gaixiang Xu, Weilai Xu, Chenxi Lu, Haiyang Yang, Yingwan Luo, Lingxu Jiang, Wei Lang, HongHu Zhu, Jie Jin, Hongyan Tong
15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study. Hematological oncology (2022)
Chen Mei, Li Ye, Yanling Ren, Xinping Zhou, Liya Ma, Gaixiang Xu, Weilai Xu, Chenxi Lu, Haiyang Yang, Yingwan Luo, Lingxu Jiang, Wei Lang, HongHu Zhu, Jie Jin, Hongyan Tong
15-days duration of Venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study. Hematological oncology (2022)
Xuefen Yan, Lu Wang, Lingxu Jiang, Yingwan Luo, Peipei Lin, Wenli Yang, Yanling Ren, Liya Ma, Xinping Zhou, Chen Mei, Li Ye, Gaixiang Xu, Weilai Xu, Haiyang Yang, Chenxi Lu, Jie Jin, Hong-Yan Tong
Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes. Cancer medicine 10 (5) (2021)
Liya Ma, Lingxu Jiang, Wenli Yang, Yingwan Luo, Chen Mei, Xinping Zhou, Gaixiang Xu, Weilai Xu, Li Ye, Yanling Ren, Chenxi Lu, Peipei Lin, Jie Jin, Hong-Yan Tong
Real-world data of chronic myelomonocytic leukemia: A chinese single-center retrospective study. Cancer medicine 10 (5) (2021)
Xinping Zhou, Chen Mei, Jin Zhang, Ying Lu, Jianping Lan, Shengyun Lin, Yuefeng Zhang, Yuemin Kuang, Yanling Ren, Liya Ma, Juying Wei, Li Ye, Weilai Xu, Kongfei Li, Chenxi Lu, Jie Jin, Hongyan Tong
Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial. Hematological oncology 38 (4) (2020)